Clinical Trial Update: An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women [Phase 3]

View source ↗

Summary

Open-label Phase 3 trial comparing romosozumab and teriparatide in postmenopausal osteoporosis completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postmenopausal Osteoporosis

Drugs mentioned

• Romosozumab (romosozumab)
• Teriparatide (Teriparatide)

Snippet

Sponsor: Amgen | Conditions: Postmenopausal Osteoporosis | Phase 3 | Status: COMPLETED | Results posted: 2018-11-08